Trial Profile

Clinical trial of rexlemestrocel-L (MPC-150-IM mesenchymal stem cells) in patients with NYHA class IV heart failure

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 21 Jun 2016

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rexlemestrocel-L (Primary)
Indications Heart failure
Focus Registrational; Therapeutic Use

Most Recent Events

14 Jun 2016 According to a MESOBLAST media release, results from this trial are expected in the second half of 2017 and will be used to support marketing approval application for rexlemestrocel-L
14 Jun 2016 According to a MESOBLAST media release, this trial is close to 60% recruited.
25 Nov 2014 The National Institutes of Health has agreed to fund this trial, according to a Mesoblast media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com